Endpoints News 生物医药· Elizabeth Cairns·· 2026-10-01AI 评分40
#EASD26:Boehringer 减肥候选药在糖尿病与肥胖领域落后于竞品
#EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesity
AI 导读
Boehringer Ingelheim 的领先肥胖候选药物在针对合并 2 型糖尿病患者的晚期临床试验中,诱发体重减轻高达 9.8%。该数据表明其在糖尿病与肥胖领域疗效落后于竞品。
正文
MILAN — Boehringer Ingelheim’s lead obesity candidate prompted weight loss of up to 9.8% in a late-stage trial in patients with both obesity and type 2 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news